What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
|
|
- Jordan Hicks
- 6 years ago
- Views:
Transcription
1 What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
2 Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through an Institutional Contract James K. Kirklin, MD
3 Circulatory Mechanical Support Circulatory Support An Harnessing Era of Disruptive Disruptive Innovation Innovation John Gibbon develops and first employs a Pump Oxygenator to perform open heart surgery May,1953
4 Dr. Christian Barnard World s First Human Heart Transplant Dec. 3,1967
5 Drs. Michael DeBakey and Denton Cooley and first artificial heart developed by Dr. Domingo Liotta used as a bridge to transplantation 1969
6 Mechanical Circulatory Support Harnessing Disruptive Innovation as Accepted Therapy The Hemopump designed by Richard Wampler Peer Portner Victor Poirier
7 Education Mechanical War Era Circulatory Cardiac SurgerySupport An Era of Disruptive Innovation XVE approved for DT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US
8 Education Mechanical War Era Circulatory Cardiac Surgery Support An Era of Disruptive Innovation XVE approved for DT Cardiowest TAH Approved for BTT
9 INTERMACS Implantation of an MCSS is not a simple, time-limited treatment episode. Because of the patient s total dependence on the device and because problems can occur at any time, clinical trial subjects should be followed closely during the trials: they and other MCSS patients should be followed, through a registry, for the remainder of their lives...maintaining a registry of MCSS recipients should be considered a routine aspect of this care The committee recommends that NHLBI support long term follow up studies of an adequate sample of MCSS patients. The Artificial Heart: Prototypes Policies and Patients; Institute of Medicine Report, A vision of John Watson and the NHLBI
10 Mechanical Circulatory Support Harnessing Disruptive Innovation as Accepted Therapy XVE approved for DT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US Award date:june 1, 2005 Duration:5 years NHLBI Contract #HHSN C To: Univ of Alabama at Birmingham PI: James Kirklin Co PI s: DavidNaftel, Robert Kormos, Lynne W. Stevenson, Cardiowest TAH Approved for BTT
11 INTERMACS: A Study in Collaboration What is INTERMACS? INTERMACS is a United States national registry for patients who are receiving durable mechanical circulatory support device therapy to treat advanced heart failure. This registry was devised as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA), clinicians, scientists and industry representatives. Interagency Registry for Mechanically Assisted Circulatory Support NHLBI Contract #HHSN C UNIVERSITY OF ALABAMA AT BIRMINGHAM ( )
12 INTERMACS PLATFORM FOR PROGRESS INTERMACS Investigators NHLBI and Federal Partners MCS Field in Rapid Evolution
13 Mechanical Circulatory Support Harnessing Disruptive Innovation as Accepted Therapy Disruptive Innovation Slow Pace of Progress Single cohort (center) Reports Clinical Trials Gradual Acculation of Persuasive Evidence Adoption for Indication INTERMACS Platform for Progress Platform for Collection and Analysis of Large Multi-institutional Data to Generate Believable Inferences Expansion of Technology into other Potential Populations of Benefit
14 Mechanical War Era Circulatory Cardiac Surgery Support Harnessing Disruptive Innovation as Accepted Therapy Era XVE approved for DT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US Cardiowest TAH Approved for BTT INTERMACS begins Data Collection
15 Mechanical War Era Circulatory Cardiac Surgery Support Harnessing Disruptive Innovation as Accepted Therapy Era XVE approved for DT HMII approved for BTT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US Cardiowest TAH Approved for BTT INTERMACS begins Data Collection
16 Mechanical War Era Circulatory Cardiac Surgery Support Harnessing Disruptive Innovation as Accepted Therapy Era XVE approved for DT HMII approved for BTT HMII - DT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US Cardiowest TAH Approved for BTT INTERMACS begins Data Collection
17 Mechanical War Era Circulatory Cardiac Surgery Support Harnessing Disruptive Innovation as Accepted Therapy Era XVE approved for DT HMII approved for BTT HMII - DT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US HVAD approved for BTT Cardiowest TAH Approved for BTT INTERMACS begins Data Collection
18 Mechanical War Era Circulatory Cardiac Surgery Support Harnessing Disruptive Innovation as Accepted Therapy Era XVE approved for DT HMII approved for BTT HMII - DT The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US HVAD approved for BTT HVAD - DT Cardiowest TAH Approved for BTT INTERMACS begins Data Collection
19 Mechanical War Era Circulatory Cardiac Surgery Support Harnessing Disruptive Innovation as Accepted Therapy Era XVE approved for DT HMII approved for BTT HMII - DT HM3 approved The NHLBI puts out an RFP for proposals to organize and run a scientific database for all durable MCS devices in the US HVAD approved for BTT HVAD - DT Cardiowest TAH Approved for BTT INTERMACS begins Data Collection
20 Goals of the Registry Facilitate the refinement of patient selection to maximize outcomes with current and new device options. Identify predictors of good outcomes as well as risk factors for adverse events after device implantation. Develop consensus best practice guidelines to improve clinical management by reducing short and long term complications of MCSD therapy. Utilize Registry information to guide improvements in technology, particularly as next generation devices evolve. Guide clinical testing and approval of new devices. INTERMACS A Platform for Progress after Innovation which quantified the challenges and benefits of this technology over the past decade
21 INTERMACS A Platform for Progress after Innovation > 60 Publications in the last 5 years 21
22 A Platform for Progress after Innovation Numerous Impact publications Crystalizing Risk Factors and Outcomes Frailty R H Failure Infection Device Exchange Destination Therapy] QOL Ambulatory HF Concomitant Surgery TR, MR Bridge to Candidacy Stroke Renal Failure Risk Factors for mortality Optimize Patient Selection Evaluate Strategies to Reduce Adverse Events 22
23 Modern Mission of INTERMACS Science Identify trends in real world experience that may reflect evolution of outcomes with changing management.
24 Implants per year Implants: June 2006 December 2016, n=18987 Continuous Flow Intracorporeal LVAD Pump - Axial Continuous Flow Intracorporeal LVAD Pump - Centrifugal Pulsatile Flow Intracorporeal TAH Pulsatile Flow Intracorporeal LVAD Pump Pulsatile Flow Paracorporeal LVAD Pump % Survival Months % Survival 1 95% 12 81% 24 70% 36 59% 48 49%
25 Modern Mission of INTERMACS Science Identify trends in real world experience that may reflect evolution of outcomes with changing management. Discern truths about outcomes and risk factors when single institution experiences remain small or isolated.
26 Implants June 2006 March 2015: TAH Survival Outcomes All adult patients implanted From June 2006 through March 2015 N=15194 patients 16467implants TAH N= 359 (2%) 3 patients have a 2 nd TAH implanted (n=362 TAH implants) % Survival TAH Implants: June 2006 March 2015, n=359 By Total Center Experience % Survival post implant at: Total Center Experience pts deaths 3 mths 6 mths 12 mths 11+ implants (n=8 hospitals) % 72% 69% 10 implants (n=36 hospitals) % 50% 36% (note: last death at 22 months) P <.0001 Event: Death (censored at transplant or device exchange) Total Artificial Heart (TAH): Survival Outcomes, Risk Factors, Adverse Events F. Arabia 1, I. Gregoric 2, V. Kasirajan 3, J. D. Moriguchi 4, D. C. Naftel 5, S. L. Myers 5, J. K. Kirklin 5. Months post Implant 26
27 Implants June 2006 March 2015: TAH Survival Outcomes Higher Early Rate of Transplantation for TAH Patients Proportion of Patients N=3473, Primary CFLVAD BTT: listed for transplant Alive (device in place) 71% Transplanted 20% Dead 8% Recovery 1% CFLVAD BTT Transplanted Alive (on a device) Dead Recovery N=359, TAH Alive (device in place) 27% Transplanted 46% Dead 27% TAH Months after Implant 27
28 Survival after LVAD implantation for ACHD vs. non-achd patients N=16,182 Total Patients in INTERMACS Database Hepatic dysfunction Early Late ACHD (n=126) 100 pt/mo Non-ACHD (n=16,056) 100 pt/mo P value <0.01 <0.01 Non-ACHD: n=16,056 ACHD: n=126 Cardiac Arrhythmia Early Late Infection Early Late Renal dysfunction Early Late < <0.01 <0.01 <0.01 Utilization and Outcomes of Ventricular Assist Device Support in Adult Congenital Heart Disease: An Analysis of INTERMACS Respiratory failure Early Late Neurological dysfunction Early Late <0.01 < C. J. VanderPluym, et al ISHLT,2016
29 Modern Mission of INTERMACS Science Identify trends in real world experience that may reflect evolution of outcomes with changing management. Discern truths about outcomes and risk factors when single institution experience remains small or isolated. Illuminate areas of controversy that require large datasets for useful analyses
30 INTERMACS: HMII Pump Investigation Implants: April 2008 June 2014, n=11123 Follow-up: Thru September 2014 Expanded Scale Primary Implants, n=9808 % Freedom from Pump Thrombosis % Freedom from pump thrombosis at Implant year 6 mths 12 mths 36 mths 48 mths % 97% 92% 89% % 97% 91% 88% % 96% 89% 86% % 93% 86% % 90% % 90% (thru Jun) 95% Event: pump thrombosis removal, transplant or death due to thrombus Year of Implant Months post implant 30
31 INTERMACS: HMII Pump Investigation Implants: April 2008 June 2014, n=11123 Follow-up: Thru September 2014 Expanded Scale Primary Implants, n=9808 % Freedom from Pump Thrombosis % Freedom from pump thrombosis at Implant year 6 mths 12 mths 36 mths 48 mths % 97% 92% 89% % 97% 91% 88% % 96% 89% 86% % 93% 86% % 90% % 90% (thru Jun) 95% Event: pump thrombosis removal, transplant or death due to thrombus Year of Implant Months post implant 31
32 Modern Mission of INTERMACS Science Identify trends in real world experience that may reflect evolution of outcomes with changing management. Discern truths about outcomes and risk factors when single institution experience remains small or isolated. Illuminate areas of controversy that require large databases for useful analyses Facilitate the introduction of new technology
33 Intermacs Role in Device Approval HMII post-market approval study Heartware Lateral Thoracotomy Trial Advisory role in Berlin Heart Pivotol Trial Advisory role in Syncardia Freedom Driver approval process
34 Modern Mission of INTERMACS Science Identify trends in real world experience that may reflect evolution of outcomes with changing management. Discern truths about outcomes and risk factors when single institution experience remains small or isolated. Illuminate areas of controversy that require Big Data for useful analyses Facilitate the introduction of new technology Provide unique insights into Adverse Events and their impact
35 Specific Adverse Events that challenge the long-term implementation of MCS Early mortality and its causes Stroke Infection of driveline and pump pockets Right Ventricular Failure Pump malfunction/ Thrombosis Renal Dysfunction GI bleeding Continuous Flow LVAD/BiVAD Implants: , n=17633 Instantaneous Death Rate (Hazard) for selected causes Deaths/Month Months post implant Cause of Death Infection RHF Neurological Device Malfunction MSOF Neurological MSOF Infection Device Malfunction RHF
36 Continuous Flow LVAD/BiVAD Implants: , n=17633 Cumulative Death Rate (Hazard) for selected causes Cumulative Hazard Cause of Death Infection RHF Neurological Device Malfunction MSOF 2017 Neurological MSOF Infection Device Malfunction RHF Months post implant
37 Education War Era Cardiac Surgery Predicting Survival and Quality of Life Demographics Clinical factors Surgical details Device factors Adverse Events Survival Time 0 3 months Pre-implant Risk Factors
38 Continuous Flow LVAD/BiVAD Implants: , n=17633 Early hazard Late hazard Pre-implant Risk Factors for Death Hazard Ratio p-value Hazard Ratio p-value Demographics Age 2 (older) 1.41 < <.0001 Female 1.47 <.0001 BMI (higher) 1.02 <.0001 Blood Type Not O White race Clinical Status ICD <.0001 INTERMACS Profile <.0001 INTERMACS Profile <.0001 Preimplant Risk Factors Intervention within 48 hours IABP Destination Therapy 1.22 <.0001 Non-Cardiac Systems Peripheral Vascular Disease Pre-COPD Albumin (lower) 0.80 <.0001 Creatinine (higher) 1.12 <.0001 Dialysis 3.29 <.0001 BUN (higher) (10 unit increase) 1.07 < <.0001 Right Heart Dysfunction RVAD in same operation 3.76 <.0001 Bilirubin (higher) (5 unit increase) 1.28 <.0001 Surgical Complexities History of cardiac surgery History of CABG Concommitant Cardiac Surgery 1.53 <.0001 Quality of Life Pre Implant Too Sick to complete EQ5D 1.65 <.0001 Worse Self Care Score (pre-implant) 1.25 <.0001
39 Education War Era Cardiac Surgery Predicting Survival and Quality of Life Demographics Clinical factors Surgical details Adverse Events Survival and QoL Implant Pre-implant Risk Factors 3 months (new time 0) Risk Factors resulting from Adverse Events
40 Continuous Flow LVAD/BiVAD Implants: , n=17633 Risk Factors for Death in Patients who were alive at 3 months postimplant (n=14,887) Constant Phase of Hazard Risk Factors Hazard ratio P-value Pre-implant Age (older) <.0001 Race: white 1.32 <.0001 Device strategy: Destination Therapy ICD prior to implant Note the relative Dominance of post- Implant events over pre-implant risk factors Clinical Events during 3 months Number of strokes 1.4 <.0001 Number of respiratory failures Number of infections 1.16 <.0001 Number of device malfunctions 1.30 <.0001 Days in acute care 1.01 <.0001 Clinical Condition at 3 months BUN (higher) 1.01 <.0001 Creatinine (higher) 1.12 <.0001 Albumin (lower) 0.97 <.0001 LDH (higher) 1.00 <.0001 Ascites Peripheral Edema Inotropes 1.70 <.0001 Warfarin (non-use) 0.74 <.0001 Impact of Adverse Events on Survival Quality of Life/Neurocognitive Visual Analog Scale (lower) <.0001 Mobility problems 1.31 <.0001 Trail making test (higher) <
41 Education War Era Cardiac Surgery Predicting Survival and Quality of Life Demographics Clinical factors Surgical details Adverse Events Survival and QoL Implant Pre-implant Risk Factors 3 months New Time 0 Risk Factors resulting from Adverse Events
42 Profile 2 Pt Continuous Flow LVAD/BiVAD Implants: , n=17633 Survival path based only on pre-implant risk factors Clinical Course During 1 st 3mths Good, uneventful % Survival Clinical Course In the current state of MCS technology, with the isolated exception of right heart failure, better risk status at implant provides limited or no protection against serious adverse events. Stroke Stroke, Infection, Inotropes Months post implant
43 Education War Era Cardiac Surgery Timeline of the MCS Evolution Era of Device Development, Understanding AEs, and Refining Optimal Populations
44 Education War Era Cardiac Surgery Timeline of the MCS Evolution Era of Devicement Development Era of Adverse Event Neutralization and Novel Devices Opportunity to Facilitate Extension of MCS to Ambulatory Advanced Heart Failure through INTERMACS studies
Predicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationSixth INTERMACS annual report: A 10,000-patient database
http://www.jhltonline.org INTERMACS ANNUAL FEATURE Sixth INTERMACS annu report: A 10,000-patient database James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationRegional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry
Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry Selim Krim, MD 1 ; Rey Vivo, MD 2 ; Patrick Campbell, MD 1 ; Jerry Estep, MD 3
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationChallenges to MCS Use in the Middle East
Challenges to MCS Use in the Middle East Feras Khaliel, MD, Ph.D Consultant Cardiac Surgeon Associate Professor of Surgery, Alfaisal Univerisity King Faisal Specialist Hospital & Research Center Dr. Michael
More informationComplications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel No disclosures Probability of survival Survival (%) Survival with LVAD Destination Bridge
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationAnalysis of Pump Thrombosis in the Intermacs Database
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationTranslating Device and Mechanical Support Guidelines to ACHD Research. Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist
Translating Device and Mechanical Support Guidelines to ACHD Research Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist Disclosures No financial disclosures May discuss off-label or investigational
More informationThe development of durable mechanical circulatory support
Advances in Heart Failure Mechanical Circulatory Support Registering a Therapy in Evolution James K. Kirklin, MD; David C. Naftel, PhD The development of durable mechanical circulatory support systems
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationVAD Mechanical Circulatory Support in ACHD as a Bridge to Recovery/Transplant or Destination Therapy
VAD Mechanical Circulatory Support in ACHD as a Bridge to Recovery/Transplant or Destination Therapy David N. Campbell MD Professor of Surgery, UC, Denver and the Children s Hospital Colorado Surgical
More informationEMS and Nursing Considerations in VAD Patient Care
EMS and Nursing Considerations in VAD Patient Care B R I T T A N Y B U T Z L E R B S N R N V A D C O O R D I N A T O R F R O E D T E R T A N D T H E M E D I C A L C O L L E G E O F W I 1 0 / 2 5 / 1 8
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationEnd Stage Heart Failure - Time to Bring the Hammer Down
End Stage Heart Failure - Time to Bring the Hammer Down Eric R. Skipper, MD, FACS Chief, Adult Cardiovascular Surgery Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support 2 3
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationHow to Develop a Comprehensive Ventricular Assist Device Program
How to Develop a Comprehensive Ventricular Assist Device Program Rodrigo V. González, MD, MS Sección de Cirugía Cardiovascular División de Cirugía Facultad de Medicina Pontificia Universidad Católica de
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More information: 2014 INTERMACS 4.0 Launches June 2, 2014
: 2014 INTERMACS 4.0 Launches June 2, 2014 David C. Naftel, PhD 1 June 2006 March 2014 UAB: DCC UNOS: WBDE 2 : 2006 What patients are receiving MCSDs? Do DT patients ever receive a transplant? What are
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationNew ventricular assist devices. FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010
New ventricular assist devices FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010 The real world of CHF Prevalence 1-3% in europe, in the age of 70-80 years up to 10-20%
More informationINTERMACS Ninth Annual Meeting Program
INTERMACS Ninth Annual Meeting Program MCSDs in 2015: Evolution, Expansion, and Evaluation Friday, May 15 2015 and Saturday, May 16 2015 Research Data Workshop Space limited Contact Grant Studdard at gkst@uab.edu
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationRecent Trials With Durable LVADs: Is There a Superior Device?
Recent Trials With Durable LVADs: Is There a Superior Device? Francis D. Pagani MD PhD Otto Gago MD Endowed Professor of Cardiac Surgery Michigan Medicine Current Device Landscape 2018 HeartMate 3 HeartMate
More informationFurther devices to treat heart failure
Postgraduate Course Heart Failure Further devices to treat heart failure Pr. Matthias Kirsch Department of Cardiac Surgery Centre Hospitalo-Universitaire Vaudois Université de Lausanne e-mail: matthias.kirsch@chuv.ch
More informationDisclosures. No disclosures to report
Disclosures No disclosures to report Update on MOMENTUM 3 Trial: The Final Word? Francis D. Pagani MD PhD Otto Gago MD Professor of Cardiac Surgery University of Michigan Ann Arbor, Michigan, USA LVAD
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationMedical Policy. MP Total Artificial Hearts and Implantable Ventricular Assist Devices
Medical Policy MP 7.03.11 BCBSA Ref. Policy: 7.03.11 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 7.03.08 Heart/Lung Transplant 7.03.09 Heart Transplant 8.01.60
More informationWhy Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care
More informationWhat s New in MCS. and Transplantation. June Transplantation. Reviews:
What s New in MCS June 2016 Kim Anderson, MD, FRCPC Advanced Heart Failure, Mechanical Circulatory Support and Transplantation Toronto General Hospital Kim.anderson@mail.utoronto.ca Farooq Sheikh, MD,
More informationAfter nearly 50 years of clinical development, durable
Advances in Mechanical Circulatory Support Mechanical Circulatory Support for Advanced Heart Failure Patients and Technology in Evolution Garrick C. Stewart, MD; Michael M. Givertz, MD After nearly 50
More informationLVADs as Destination Therapy: When Best Practice Criteria Meets the Real World
LVADs as Destination Therapy: When Best Practice Criteria Meets the Real World Farooq Sheikh, M.D., FACC Advanced Heart Failure Program MedStar Washington Hospital Center Disclosure I have no relevant
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationHISTORICAL PERSPECTIVES OF MECHANICAL CARDIAC ASSIST
HISTORICAL PERSPECTIVES OF MECHANICAL CARDIAC ASSIST Rohinton J. Morris, MD Chief- Cardiothoracic Surgery, Abington-Jefferson Health Systems PROGRAM Past From inception to clinical use Present Devices,
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationIntegrating Innovative Technologies into the Care of Cardiac Patients
Integrating Innovative Technologies into the Care of Cardiac Patients Marc J. Semigran MD Medical Director, Heart Failure & Cardiac Transplantation MGH Associate Professor Harvard Medical School Presenter
More informationMechanical Circulatory Support for Unstable Heart Failure
Mechanical Circulatory Support for Unstable Heart Failure Michael A. Acker, MD William Measey Professor of Surgery Chief of Cardiovascular Surgery University of Pennsylvania Health System O.H. Frazier,
More informationHow to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationFacts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.
10/21/18 1 Facts 5.8 million adults in the US have heart failure. About ½ of those who have HF have a 5 year life expectancy. STRONG Risk Factors for HF* Coronary Heart Disease/MI/Afib COPD Renal Failure
More informationNone. Declaration of conflict of interest
None Declaration of conflict of interest New Long Term Circulatory Support Technology and Treatment Strategies Stephen Westaby Oxford, UK Cardiac Transplantation: Facts from the UNOS Database Median survival
More informationStrengthening Your VAD Program
Disclosure: I have no financial conflicts of interest. Strengthening Your VAD Program Octavio E. Pajaro MD, PhD Chair, Cardiothoracic Surgery Mayo Clinic Arizona Surgical Director, Heart Transplantation
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Total Artificial Hearts and Ventricular Assist Devices Page 1 of 39 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Total Artificial Hearts and Ventricular Assist
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationLeft ventricular assist devices current state and perspectives
Review Article Left ventricular assist devices current state and perspectives Anatol Prinzing 1, Ulf Herold 1, Anna Berkefeld 2, Markus Krane 1,3, Rüdiger Lange 1,3, Bernhard Voss 1 1 Department of Cardiovascular
More informationClinical Policy: Total Artificial Heart Reference Number: CP.MP.127
Clinical Policy: Reference Number: CP.MP.127 Effective Date: 12/16 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationCandidate Selection for Long Term VAD
6th Saudi Heart Failure Symposium Riyadh - December 9, 2017 Candidate Selection for Long Term VAD AMMAR CHAUDHARY, MBCHB, FRCPC Consultant Cardiologist Advanced Heart Failure Department of Cardiology King
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2017 Origination: 12/2001 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationDisclosures. Overcoming TAH Challenges: Innovation in PT Practice. Learning Objectives. Outline. Cedars-Sinai Medical Center.
Disclosures Overcoming TAH Challenges: Innovation in PT Vicky Hu no relevant financial relationship exists Suzanne Seidel no relevant financial relationship exists Suzanne Seidel, PT, CCS Vicky Hu, PT,
More informationMechanical Circulatory Support for the Failing Heart Progress, Pitfalls and Promises
Heart, Lung and Circulation (2015) 24, 527 531 1443-9506/04/$36.00 http://dx.doi.org/10.1016/j.hlc.2015.02.004 EDITORIAL Mechanical Circulatory Support for the Failing Heart Progress, Pitfalls and Promises
More informationName of Policy: Ventricular Assist Devices and Total Artificial Hearts
Name of Policy: Ventricular Assist Devices and Total Artificial Hearts Policy #: 033 Latest Review Date: February 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Total Artificial Hearts and Ventricular Assist Devices Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Total Artificial Hearts and Ventricular Assist
More informationEnd-Stage Heart Failure Care: Advances in Technology and Patient Survival
End-Stage Heart Failure Care: Advances in Technology and Patient Survival Colleen Ciampa, RN, MN, CNS, NP-C St. Vincent Hospital Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Program
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationMultiple case reports of successful use, with only one case report of intra device thrombotic event
rfviia in VAD Patients Limited data exist regarding safety Multiple factors increase pro thrombotic potential Multiple case reports of successful use, with only one case report of intra device thrombotic
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationECMO AND SHORT-TERM SUPPORT:
ECMO AND SHORT-TERM SUPPORT: UTILIZATION GUIDELINES AND IMPACT OF THE NEW HEART ALLOCATION SYSTEM Jeffrey Teuteberg Section Chief of Heart Failure, Cardiac Transplant and Mechanical Circulatory Support
More informationGiving your heart strength. Ventricular Assist Device.
Giving your heart strength. Ventricular Assist Device. 1 National leader in Ventricular Assist Devices Although you may be nervous when considering heart surgery, you can rest assured knowing that UR Medicine
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More informationDestination Life in Japan and the United States: A new lifestyle for heart failure patients with left ventricular assist devices
Michael Yamakawa 1 Destination Life in Japan and the United States: A new lifestyle for heart failure patients with left ventricular assist devices Michael Yamakawa Biophysics Johns Hopkins University
More informationA thesis submitted to the. Graduate School. of the University of Cincinnati. in partial fulfillment of the. requirements for the degree of
Virtual Implantation Of Mechanical Circulatory Support Devices A thesis submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Master
More informationSelecting Patients for the SynCardia temporary Total Artificial Heart Help Your Patients Live Longer, Live Better
Selecting Patients for the SynCardia temporary Total Artificial Heart Help Your Patients Live Longer, Live Better The SynCardia Total Artificial Heart (TAH) is a clinically proven life-saving treatment
More informationISHLT ACADEMY MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT (MCS)
ISHLT ACADEMY MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT (MCS) Saturday, April 30, 2016 1:45 PM 6:30 PM Marriott Wardman Park Hotel, Washington, DC, USA WASHINGTON BALLROOMS 1 & 2 ISHLT ACADEMY MASTER
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationReview Article Current Status of Mechanical Circulatory Support: ASystematicReview
Cardiology Research and Practice Volume 2012, Article ID 574198, 12 pages doi:10.1155/2012/574198 Review Article Current Status of Mechanical Circulatory Support: ASystematicReview Kyriakos Spiliopoulos,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts
Implantable Ventricular Assist Devices and Total Artificial Hearts Policy Number: Original Effective Date: MM.06.017 05/21/1999 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More information